Inmune Bio (INMB) Non-Current Deferred Tax Liability (2021)

Inmune Bio (INMB) posted Non-Current Deferred Tax Liability of $257000.0 for Q4 2021.

Inmune Bio (INMB) Non-Current Deferred Tax Liability (2021) Analysis & Trends

Inmune Bio has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $257000.0 in Q4 2021.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $257000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $257000.0 (changed N/A YoY) and the FY2021 annual result came in at $257000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability steadied at $257000.0 in Q4 2021 per INMB's latest filing.
Over five years, Non-Current Deferred Tax Liability peaked at $257000.0 in Q4 2021 and troughed at $257000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Inmune Bio	61.59 Mn	43.18 Mn	-

Download Data

Date	Value
Dec 31, 2021	257,000.00
Dec 31, 2021	257,000.00